Eidelman Eric, Tripathi Hemantkumar, Fu De-Xue, Siddiqui M Minhaj
Division of Urology, Department of Surgery, University of Maryland School of Medicine, Baltimore, MD, USA.
Transl Androl Urol. 2018 Sep;7(Suppl 4):S490-S497. doi: 10.21037/tau.2018.04.08.
Prostate cancer treatment is based on the stratification of disease as low-, intermediate- or high-risk. This stratification has been largely based on anatomic pathology of the disease, as well as through the use of prostate specific antigen (PSA). However, despite this stratification, there remains heterogeneity within the current classification schema. Utilizing a metabolic approach may help to further establish novel biomolecular markers of disease aggressiveness. These markers may eventually be useful in not only the diagnosis of disease but in creating tumor specific targeted therapy for improved clinical outcomes.
前列腺癌的治疗是基于将疾病分为低风险、中风险或高风险进行分层的。这种分层很大程度上基于疾病的解剖病理学，以及通过使用前列腺特异性抗原（PSA）。然而，尽管有这种分层，当前的分类模式中仍存在异质性。采用代谢方法可能有助于进一步建立疾病侵袭性的新型生物分子标志物。这些标志物最终不仅可能有助于疾病的诊断，还能用于创建肿瘤特异性靶向治疗以改善临床结果。
